BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27

• Press Releases

  Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow

  July 17, 2026

   · 

  2 min read
• Press Releases

  Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

  July 17, 2026

   · 

  5 min read
• Press Releases

  Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

  July 17, 2026

   · 

  13 min read
• Press Releases

  Mirador Therapeutics Expands Precision Immunology Portfolio with Exclusive License to KP-301, a Long-Acting Anti-C5a Antibody

  July 17, 2026

   · 

  3 min read
• Press Releases

  TRELLIS BIOSCIENCE RAISES $9 MILLION TO ADVANCE CLINICAL DEVELOPMENT OF CALPURBATUG (TRL1068)

  July 17, 2026

   · 

  4 min read
• Press Releases

  IPG Photonics Announces Binding Offer to Acquire Lumibird Medical, Expanding IPG’s Medical Laser Growth Platform

  July 17, 2026

   · 

  7 min read
• Press Releases

  LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH (OH) to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline

  July 17, 2026

   · 

  5 min read
• Press Releases

  Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

  July 17, 2026

   · 

  19 min read
• Press Releases

  Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

  July 17, 2026

   · 

  9 min read
• Press Releases

  Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 2026

  July 17, 2026

   · 

  2 min read